Panelists:
Chantelle Gaskin
Field Applications Specialist
Thermo Fisher Scientific
Ganesh Krishnamoorthy, PhD
Director Downstream Process Development
Forge Biologics
Stephen Soltys
Chief Manufacturing Officer
Kriya Therapeutics
- Time:
The rapid growth of gene therapy programs across a host of different diseases has been made possible in large part by our increased understanding of the efficiency and safety profiles of adeno-associated virus (AAV) vectors. To maximize the chances of success, AAV purification is a critical step in developing such programs, requiring researchers to solve a number of key downstream challenges.
In this timely roundtable discussion, a trio of distinguished experts in AAV purification and process development will share their expertise and best practices in tackling and solving downstream AAV purification challenges. Among the themes to be discussed will be industry trends, platform ability and the relentless need for innovation. Our guest panelists are:
· Ganesh Krishnamoorthy, PhD – Director Downstream Process Development, Forge Biologics
· Stephen Soltys – VP Process Development, Kriya Therapeutics
· Chantelle Gaskin – Field ApplicationScientist, Thermo Fisher Scientific
A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelists.
Produced with support from:
